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Introduction  
Breast milk is becoming widely recognized as the superior form of nutrition for infant 
feeding. When compared to formula, infants fed breast milk are less likely to have 
gastrointestinal complications, higher IQ, and positive long term effects such as reducing their 
rates of obesity and diabetes as adults ​(Chantry et al. 2015)​. However, breast milk was never 
made to replace a placenta and for premature infants, they will need a more complex diet to 
ensure their adequate growth and development. In this regard, human milk fortifiers have 
revolutionized neonatal nutrition. However, there is still debate on the clinical outcomes in 
amplifying the nutrients in breast milk when combined with human-based milk fortifier (HBF), 
or bovine-based milk fortifier (BBF), and whether or not an exclusively human milk diet has 
positive effects on infant health.  
 
Components of Breastmilk  
In order to fully understand the differences between HBF and BBF a brief look into the 
unique qualities in breast milk is necessary. Breast milk is primarily composed of lipids, ranging 
from 40-55% of the total energy ​(Andreas et al. 2015)​. Triacylglycerides comprise 98% of the 
lipid profile in breast milk, followed by diacylgylcerides, monoacylglycerides, free fatty acids, 
phospholipids, and cholesterol, all of which are packaged into milk lipid globules ​(Andreas et al. 
2015)​. Sphingomyelins are present in the membrane of this globule and are critical for central 
nervous system myelination, in addition to improving the neurobehavioural development of 
low-birthweight infants ​(Andreas, Kampmann, & Mehring Le-Doare, 2015)​. The lipids in 
breastmilk have also been associated with potent cytolytic effects on intestinal parasites, 
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gram-positive bacteria, and yeast ​(Andreas et al. 2015)​. Lysozymes, which are present in human 
milk 3,000 times more than in bovine milk, can break down the outer cell wall of gram-positive 
bacteria and in some gram-negative bacteria. The immunoglobulins in lactation are widely 
known to provide protection to the infant while their immune system matures. Secretory IgA 
(SIgA) is the primary antibody present in breast milk, protecting against pathogens via a 
multitude of ways. SIgA prevents adherence to epithelial cell surfaces by immobilizing 
pathogens and neutralizes toxins and virulence factors. Due to SIgA’s relative aversion to 
proteolysis, it can withstand the gastrointestinal tract’s quick cell turnover rate and further 
protect against pathogens ​(Andreas et al. 2015)​. Breast milk’s SIgA can protect from a variety of 
pathogens, such as: ​Vibrio cholerae, Campylobacter, Shigella, Giardia lamblia,​ and respiratory 
tract infections ​(Andreas et al. 2015)​. Additionally, sodium nitrate in breast milk provides better 
blood flow to the gastrointestinal tract which can lower rates of necrotizing enterocolitis.  
 
Unique Care for Preterm Infants 
As neonatal intensive care modernized with improved medical interventions, infants’ 
survival rates also improved. The primary concern for premature infants is immaturity of the 
respiratory system, resulting in low surfactant in the lungs to maintain breathing. However, with 
the introduction of Continuous Positive Airway Pressure (CPAP) in 1971, infants who received 
this intervention had an 80% survival rate ​(Dillard 2016)​.  
Similarly, feeding was a concern for infants in the 1970’s because of the reliance on term 
formula. Formula contained 82% casein protein and 18% whey protein. It became increasingly 
apparent that this ratio increased acid accumulation in the gut, or could even cause a lactobezoar. 
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A lactobezoar is a solid mass of protein that would collect and potentially perforate the stomach, 
threatening the life of an infant. As the ratio became closer to that of breast milk (40% casein, 
60% whey) feeding resilience began to increase both in initiation and volume tolerance ​(Dillard 
2016)​.  
One of the most fearsome diseases that can affect a premature infant is necrotizing 
enterocolitis (NEC) which is associated with bacterial infections, poor perfusion of blood in the 
intestines, and enteral feeding. The peak incidence (15%) of NEC and the leading cause of death 
in this developmental stage, is around 24 weeks gestation, a gestational age where being 
categorized as very low birth weight (<1500 grams) is more common. Those who survive are at a 
higher risk for significant neurodevelopmental impairments as well as a host of other short and 
long term complications ​(Learning in 10 2018)​. Although it is not known why this disease occurs 
in premature infants, nor is there a cure, human milk has been shown to be protective against 
NEC ​(Chantry et al. 2015)​.  
 
(Neu and Walker 2011) 
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Human Milk Fortifiers (HMF) 
Although breast milk’s benefits are expansive, it cannot compare to the rapid 
development that occurs in utero during the third trimester. Therefore, as neonatal care became 
more impressive, so did the need for a nutritional product that could boost the advantageous 
profile of breast milk. A mother’s milk will have a higher protein content if their child is born 
prematurely for about one month, a necessary change to promote growth, yet one that is only 
short term. However, the use of non-sterile powder formulas is generally discouraged in this 
immunocompromised population due to the fear of infection. Fortifiers became a means to 
extend this higher protein content to aid in the rapid growth of the premature infant. The 
American Academy of Pediatrics (AAP) recommends fortifying mother’s milk or pasteurized 
donor human milk with protein, minerals, and vitamins to ensure optimal nutrition intake. 
(Bakewell-Sachs et al. 2009)​. 
Breast milk and its many benefits, briefly spoken about above, demonstrates that it is the 
optimal food source for an infant of any age. Coupled with the knowledge of the unique physical 
condition a premature infant experiences, the need to add fortifier to breast milk is apparent. 
Currently, the only human-based human milk fortifier regulated by the FDA and on the market is 
by Prolacta Bioscience.  
 
Ingredients 
In the neonatal world, daily energy requirements are calculated and divided by kilograms 
as a reference point. For premature infants being enterally fed, the requirements are between 105 
to 130 kcal/kg per day ​(Texas Children's Hospital )​. Infants being parenterally fed need less 
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energy due to the concentrated dose of nutrition they receive. Additionally, being more critically 
ill results in less fecal energy loss, fewer episodes of cold stress, and less activity overall. Their 
requirements are around 90-100 kcal/kg per day ​(Texas Children's Hospital )​. Infants that are ill 
with a chronic illness may need more calories per day due to an increased resting energy 
expenditure (REE).  
Nutrient Requirements of Preterm Infants in Comparison to Intakes Provided from Unfortified 
and Fortified Human Milk  
Nutrients Nutrient 
Requirements 
for preterm 
infants <1500 g 
Unfortified 
20 kcal/oz 
Breast 
milk* 
24 kcal/oz 
Breast milk + 
HMF* 
27 kcal/oz 
Breast milk + 
HMF  
30 kcal/oz high 
protein breast 
milk + HMF 
Fluids ml/kg — 180 150 133 120 
Energy 
(kcal/kg) 
120 120 120 120 120 
Protein (g/kg) 4 1.8 3 3.4 4.1 
*Feeding Type (content based on use of Powdered Similac HMF) 
When analyzing the ingredients present in breast milk that can benefit premature babies, 
human milk oligosaccharides (HMOs) first come to mind. HMOs were discovered as a prebiotic 
that serves as a metabolic substrate for the bacteria ​Bifidobacterium ​which helps shape intestinal 
microbiota composition ​(Bode 2012)​.With over 200 identified HMOs, human milk  has more 
complex variations and a higher concentration of HMOs than any other mammalian milk ​(Bode 
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2012)​. There are 5 monosaccharides that can create HMOs: glucose, galactose, 
N-acetylglucosamine, fucose, and sialic acid. The first two monosaccharides bond together to 
form the disaccharide lactose, the structural backbone of HMOs ​(Bode 2012)​. As these complex 
sugars are ingested, they pass through the entire gastrointestinal tract to land in the large 
intestine. There, among the highly dense bacterial environment, they are eaten by the bacteria 
and contribute to the immune system. The variety of HMO’s present also diversifies the different 
biological functions that they contribute to. HMO’s functions include:  
● Enhance and sustain growth of beneficial gut bacteria ​(Smilowitz et al. 2014)​.  
● Prophylactically bind harmful bacteria, viruses, and toxins to allow for their excretion 
(Smilowitz et al. 2014)​.  
● Improve intestinal epithelial barrier function by supporting beneficial bacteria ​(Smilowitz 
et al. 2014)​.  
● Support maturation and regulation of the immune system ​(Jantscher-Krenn and Bode 
2012)​.  
Prolacta fortifier claims to be the only nutritional product that contains a wide variety of HMOs 
due to their large starting pools. Additionally, traditional pasteurization methods do not affect the 
variety of the HMOs in their fortifying products.  
 
Indicated Use  
There is not a clearly defined initiation process of beginning to fortify milk with human 
milk fortifier, and therefore each hospital’s protocol may differ slightly. Forsyth Medical Center 
in Winston Salem, North Carolina begins fortifying with human milk fortifier for infants with a 
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birth weight <2000 grams, gestational age < 34 weeks, or any premature infants demonstrating 
inadequate intake or growth. HMF is initiated when an infant is tolerating feeds of 80 mL/kg/day 
at a dose of 1 pack per 50 mL. Once tolerating 100 mL/kg/day, the dose is increased to 1 pack 
per 25 mL. Similarly, the University of Iowa Stead Family Hospital begins fortifying milk for all 
breast milk fed infants weighing less than 2000 grams.  Infants weighing 2000 – 2500 grams 
may also benefit from the addition of HMF, particularly if they are SGA or demonstrated poor 
intake and/or growth ​(Guidelines for the use of human milk ...)​. Initiation protocol is as follows:  
1. Human Milk Fortifier (24 kcal/oz) should be initiated when the infant is tolerating breast 
milk feeds of > 25 ml\L/day.  Infants receiving 25 mL of breast milk on the first day of 
feeds should wait until day of life three or four before starting HMF. 
2. Infants who have been tolerating breast milk and HMF feeds and are made ​nil per os 
(​NPO) should be restarted on breast milk and HMF feeds. 
3. Indications for using concentrated breast milk feeds (27 kcal/oz or 30 kcal/oz high 
protein) in infants include: 
a. Fluid restriction < 140 ml/kg 
b. Poor weight gain (< 10 – 15 g/kg/d) on 120 kcal/kg of 24 kcal/oz Breast Milk and 
HMF 
c. Metabolic bone disease (alkaline phosphatase > 600 U/L) with poor bone 
mineralization on x-ray requiring increased intakes of calcium and phosphorus. 
(Guidelines for the use of human milk ...) 
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Monitoring guidelines include checking electrolytes on a weekly basis until they are 
within a normal range and the infant is no longer receiving intravenous fluids or oral electrolyte 
supplements, as well as paying close attention to calcium and phosphorous levels due to the 
possibility of high mineral intake from fortification.  
The Academy of Breastfeeding Medicine suggests that the discharge plan for infants 
receiving fortified milk begin one week in advance, transitioning the infant to unfortified human 
milk, ad libitum. During this time their growth will be monitored, and if not exclusively 
breastfeeding, monitoring milk intake as well. If growth is adequate, this is an appropriate 
discharge plan. However, if discharge follow-up can be scheduled quickly (within one or two 
days), the infant can transition off fortified human milk, ad libitum at any time before discharge 
without one week of inpatient monitoring ​(Chantry et al. 2015)​. 
 
Effectiveness 
There is a small, but growing, body of literature on the efficacy of HBF and how it’s 
implementation could impact neonatal nutrition. Furthermore, with the new onset of human 
based human milk fortifier (HBF), there is an increasing amount of research dedicated to it’s 
comparison to bovine based human milk fortifier (BBF).  
In a study comparing the in vitro antioxidant and oxidative compounds within raw and 
pasteurized human milk, two different preterm infant formulas, three bovine milk-based fortifiers 
and two experimental donkey milk-based fortifiers, HBF was shown to reduce rates of NEC 
(Pozzo et al. 2019)​. Incidence of NEC was lower ​(Assad et al. 2016)​ in very low birth weight 
infants on an exclusively HBF when assessed in a level III NICU. ​However, in very preterm 
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infants there has not been conclusively ​statistically significant differences in NEC incidence 
nevertheless, significantly fewer infants fed the complete exclusive human milk diet (EHMD) 
experienced surgical NEC (​Cristofalo et al. 2013)​ which has a higher mortality rate.  
The primary outcome of the latter study was the number of days on parenteral nutrition 
each preterm infant experienced. The median amount of days was 36 versus 27 in BBF and HBF 
fed infants, respectively ​(Cristofalo et al. 2013)​. Additionally, in the same study as above that 
compared the in vitro antioxidant and oxidative compounds within raw and pasteurized human 
milk, HBF was shown to decrease duration of​ ​parenteral nutrition ​(Pozzo et al. 2019)​. 
 Some theories predict that the positive results we see are not due to the antioxidative 
components within human milk, but rather the results are from minimizing the oxidative 
components found in other non-human-based milks. ​Furthermore, in a study measuring fecal 
calprotein, a marker of gut inflammation and a risk factor for NEC, in infants born weighing less 
than 1250 grams and fed an exclusive human milk diet, the use of HBF in comparison to BBF 
did not show an improvement in feeding tolerance, reduced mortality, nor morbidity. ​(O'Connor 
et al. 2018)​. ​One study included 293 infants between gestational ages 23 to 34 weeks and birth 
weights between 490 and 1700 grams. Feeding intolerance occurred less often, number of days 
to full feeds was lower, incidence of NEC was lower ​(Assad et al. 2016)​  and total 
hospitalization costs were lower by up to $106,968 per infant in those fed an EHM diet 
compared with the other groups.  
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(Pozzo et al. 2019) 
 
Average weight gain per day was similar among the four groups (18.5 to 20.6 grams per 
day) ​(Assad et al. 2016)​. However, when compared specifically to bovine-based human milk 
fortifier, there is not a consensus on whether either one is superior than the other as far as weight 
gain. In regards to a study conducted on extremely low birth weight infants (<1000 grams), there 
was no conclusion that HBF was better than BBF. In fact, those receiving HBF had a 
significantly lower growth velocity​ ​than those receiving BBF ​(Eibensteiner et al. 2019)​. ​An 
EHMD has been shown to decrease another comorbidity of prematurity, severe retinopathy. 
When compared to BBF, HBF reduced incidence of retinopathy, even though infants were 
receiving human milk in both study groups ​(Taylor 2019)​.​ Additionally, morbidities such as 
late-onset sepsis and bronchopulmonary dysplasia are decreased with higher doses of human 
milk, though significant differences are not apparent in exclusive human milk diet studies 
(Taylor 2019)​ which shows the potential promise in conducting further research on EHMD’s. 
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The field of EHMD is relatively new, and therefore there is yet to be consensus on the true 
impact. 
 
Cost 
The immunoprotective factors in human milk may also play a role in reducing medical 
costs incurred by both parents and hospitals. It is unclear if the effects are seen due to breast milk 
lining the immature gut mucosa or rather because of the absence of harmful antigens that can be 
found in non-human-based products. In 2011, the adjusted incremental costs of medical and 
surgical NEC above the average cost incurred for extremely premature infants in the NICU was 
$74,004 and $198,040 per infant, respectively.  
“Extremely premature infants fed with 100% human-milk based products had lower 
expected NICU length of stay and total expected costs of hospitalization, resulting in net direct 
savings of 3.9 NICU days and $8,167.17 ​(Ganapathy et al. 2012)​”  Additionally, in a 
retrospective study conducted on 293 infants, total hospitalization costs were lower by up to 
$106,968 per infant in those fed an exclusively human milk diet compared with the other groups. 
Similarly, a study including 293 infants between gestational ages 23 to 34 weeks and birth 
weights between 490 and 1700 grams showed that feeding intolerance occurred less often, 
number of days to full feeds was lower, incidence of NEC was lower, and total hospitalization 
costs were lower by up to $106,968 per infant in those fed an EHM diet compared with the other 
groups ​(Assad et al. 2016)​. 
 
 
 
13 
Discussion  
Human milk based fortifier has been shown to reduce the incidence of NEC in very low 
birth weight infants, however this finding was not found in preterm infants. The latter study also 
showed reduced surgical NEC when exposed to an exclusive human milk diet in those same 
preterm infants. Additionally, there has been research to show that HBF decreased the amount of 
days on parenteral nutrition, feeding intolerance, number of days to full feeds, and costs per 
infants were lowered by over $100,000. However, when looking specifically at gut 
inflammation, there did not seem to be a difference between HBF and BBF. Human milk has 
been cited as a lower inflammatory food and inflammation is known to contribute to NEC, 
however more studies need to be conducted on how these two factors interplay within an infants 
gut and what other factors within the NICU setting may be contributing to inflammation. 
Furthermore, growth velocity does not appear better in infants fed with HBF versus BBF, 
however according to the WHO growth charts, healthy term, breastfed babies tend to have a 
lower weight at around three months compared to formula fed babies which may be human’s 
biological inclination reflected in NICU care. Additionally, HBF has been shown to decrease 
other comorbidities in the preterm infants including, severe retinopathy, late-onset sepsis, and 
bronchopulmonary dysplasia. ​As this budding area of research expands, the ultimate motive is to 
create a protocol surrounding human milk fortification in NICU settings that is backed by 
evidence-based research.  
Most of the aforementioned studies did not look at the discrepancies between their results 
and races of the infant and mother. As is well-documented, there are significant health disparities 
in America, which are similarly reflected in the NICU setting. As initiative is being taken in the 
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public health world to increase access and ease of breastfeeding to people of color and their 
infants, the role of human milk fortifier is yet to be addressed. As research expands on the 
benefits of an EHMD, there is the potential for advocating for this type of diet and how it may 
help reduce racial inequities within the neonatal realm.  
 
Public Health and Clinical Implications 
As with all healthcare in the United States, there are significant inequalities due to 
structural racism that need to be accounted for if access to optimal care for all infants is to be a 
goal. According to the CDC, compared to 86.6% of non-Hispanic white infants and 82.9% of 
Hispanic white infants only 74% of non-Hispanic black infants were ever breastfed ​(CDC 2019)​. 
The world of motherhood is convoluted with twists and turns of guilt, judgement, and 
unwavering cultural norms. Coupled with a new birth of a sick child, many factors can influence 
a woman’s decision to start and continue breastfeeding. Having a lack of support both in the 
familial or cultural sense, limited information about breastfeeding, and an unsupportive work 
environment can all contribute to a women’s early cessation of breastfeeding ​(Anstey et al. 
2017)​. Additionally, some of these factors disproportionately impact women of color, especially 
black women who are twice as likely to give birth to premature babies (14%) in comparison to 
white mothers (9)% ​(Preterm Birth | Maternal and Infant H...)​. Black women are more likely to 
be affected by an earlier return to work, inadequate education about breastfeeding from 
providers, and lack of access to breastfeeding support that all can impact her decision to 
breastfeed and the duration of breastfeeding ​(Johnson et al. 2015)​. One study examining 
hospital-based support for breastfeeding found that facilities less likely to meet five indicators 
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for supportive breastfeeding practices were also facilities within zip codes that had higher than 
the national average of black residents. These practices included early initiation of breastfeeding, 
minimal use of breastfeeding supplements and pacifiers, rooming-in, and providing support 
post-discharge for mothers ​(Lind et al. 2014​). The hurdles that black women have to face will 
undoubtedly affect their relationship with breastfeeding, regardless if it is the most beneficial 
nutrition for their babies. The socioecological model (SEM) demonstrates how the environment 
that one lives in can affect their most intimate decision making. The information surrounding the 
benefits of breastfeeding is rather ubiquitous, so rather than a focus on ​why ​breastfeeding is best, 
public health efforts should be placed on educating providers and policy makers on ​what​ is 
making sustaining breastfeeding so hard, especially for mothers of sick babies. In 2011, ​The 
Surgeon General’s Call to Action to Support Breastfeeding​ outlined 20 action steps to support 
breastfeeding across various sectors of society, including a call to better understand and address 
breastfeeding disparities ​(Lowe 2011)​.  “A U.S.-based review of randomized trials evaluating 
breastfeeding interventions targeting minorities showed that group prenatal education, peer 
counseling interventions, breastfeeding-specific clinic appointments, and enhanced hospital 
practices/WIC-based services positively affected breastfeeding outcomes among minority 
women.” Moreover, the CDC is currently funding a quality improvement project in hospitals to 
support the implementation of these evidence-based maternity care practices ​(Anstey et al. 
2017)​.  
Furthermore, there are socioeconomic factors to consider. Infants eligible and who 
participate in the Special Supplemental Nutrition Program for Women, Infants, and Children 
(WIC) are the least likely to ever be breastfed (75.5%), in comparison to those that are eligible 
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but do not participate in WIC (89%) and infants who are not eligible (92.7%) ​(CDC 2019)​.  As 
the importance of human milk becomes a standard in medical practice, the question has to be 
framed in such a way that those who are marginalized are not further disenfranchised in the 
pursuit of optimal medicine. In the clinical setting, these health disparities can manifest 
themselves in mothers not having the resources, nor the support to sustain breastfeeding for their 
infants in the NICU. These infants may be more likely to experience a myriad of health 
outcomes that can affect both short and long term development, further perpetuating the cycle of 
poor health in families that struggle to break free.  
 
Conclusion 
Human milk has extraordinary qualities that are uniquely designed for infants and their 
nutritional needs, including those related to immunity, neurodevelopment, and gut health, all of 
which are further magnified when considering the care of preterm infants. In order to achieve 
adequate growth these immunocompromised infants need breastmilk to be fortified. As of now, 
there is no conclusive evidence that human milk based fortifiers are superior to bovine milk 
based fortifiers, however, their effects ​of shortening duration of parenteral nutrition, and 
reducing rates of NEC and costs have been documented. Although there is no question that 
breast milk is the optimal form of nutrition for an infant, there are racial and socioeconomic 
disparities across all breastfeeding targets, inclusive of initiation, exclusivity, and duration.  As 
more studies are conducted on this newer supplement in the world of neonatal nutrition, there 
needs to be a thoughtful discussion on how best to ensure all sick babies are provided human 
milk, whether fortified or not.  
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